Literature DB >> 9648871

Tissue transglutaminase is an in situ substrate of calpain: regulation of activity.

J Zhang1, R P Guttmann, G V Johnson.   

Abstract

Tissue transglutaminase (tTG) is a calcium-dependent enzyme that catalyzes the transamidation of specific polypeptide-bound glutamine residues, a reaction that is inhibited by GTP. There is also preliminary evidence that, in situ, calpain and GTP may regulate tTG indirectly by modulating its turnover by the calcium-activated protease calpain. In the present study, the in vitro and in situ proteolysis of tTG by calpain, and modulation of this process by GTP, was examined. tTG is an excellent substrate for calpain and is rapidly degraded. Previously it has been demonstrated that GTP binding protects tTG from degradation by trypsin. In a similar manner, guanosine-5'-O-(3-thiotriphosphate) protects tTG against proteolysis by calpain. Treatment of SH-SY5Y cells with 1 nM maitotoxin, which increases intracellular calcium levels, resulted in a significant increase in in situ TG activity, with only a slight decrease in tTG protein levels. In contrast, when GTP levels were depleted by pretreating the cells with tiazofurin, maitotoxin treatment resulted in an approximately 50% decrease in tTG protein levels, and a significant decrease in TG activity, compared with maitotoxin treatment alone. Addition of calpain inhibitors inhibited the degradation of tTG in response to the combined treatment of maitotoxin and tiazofurin and resulted in a significant increase in in situ TG activity. These studies indicate that tTG is an endogenous substrate of calpain and that GTP selectively inhibits the degradation of tTG by calpain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9648871     DOI: 10.1046/j.1471-4159.1998.71010240.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

1.  The Differential Effects of R580A Mutation on Transamidation and GTP Binding Activity of Rat and Human Type 2 Transglutaminase.

Authors:  Qingmin Ruan; Janusz Tucholski; Soner Gundemir; Gail V W Johnson Voll
Journal:  Int J Clin Exp Med       Date:  2008-06-30

2.  Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis.

Authors:  G D'Argenio; M Calvani; N Della Valle; V Cosenza; G Di Matteo; P Giorgio; S Margarucci; O Petillo; F P Jori; U Galderisi; G Peluso
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 3.  Transglutaminases: nature's biological glues.

Authors:  Martin Griffin; Rita Casadio; Carlo M Bergamini
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

Review 4.  Transglutaminase 2 inhibitors and their therapeutic role in disease states.

Authors:  Matthew Siegel; Chaitan Khosla
Journal:  Pharmacol Ther       Date:  2007-05-13       Impact factor: 12.310

5.  Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: implications for the pathogenesis of Parkinson disease.

Authors:  Adrien W Schmid; Diego Chiappe; Vérène Pignat; Valerie Grimminger; Ivan Hang; Marc Moniatte; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2009-01-21       Impact factor: 5.157

6.  Tissue transglutaminase (TG2) facilitates phosphatidylserine exposure and calpain activity in calcium-induced death of erythrocytes.

Authors:  Z Sarang; A Mádi; C Koy; S Varga; M O Glocker; D S Ucker; S Kuchay; A H Chishti; G Melino; L Fésüs; Z Szondy
Journal:  Cell Death Differ       Date:  2007-07-06       Impact factor: 15.828

7.  Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation.

Authors:  Gozde Colak; Jeffrey W Keillor; Gail V W Johnson
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

8.  Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury.

Authors:  Matthew Siegel; Pavel Strnad; R Edward Watts; Kihang Choi; Bana Jabri; M Bishr Omary; Chaitan Khosla
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

9.  Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain.

Authors:  Wen G Jiang; Lin Ye; Andrew J Sanders; Fiona Ruge; Howard G Kynaston; Richard J Ablin; Malcolm D Mason
Journal:  J Transl Med       Date:  2013-10-25       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.